RxDoctor Payments Data

Daniel Levin, MD

Clinical Cardiac Electrophysiology · Albuquerque, NMNPI 1952796997

Payments from drug & device makers

What this record shows

The money is spread across several categories — grants (58.1%), food and beverage and travel and lodging — rather than concentrated in one kind of arrangement. Medtronic accounts for 89.0% of it on its own, with 14 other manufacturers making up the rest. Reporting peaked in 2022 at $20,726 and has fallen 82.0% since, to $3,736 in 2025.

$43,922in general payments, 2019–2025

Across 245 payments — averaging $179.28 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Medtronic$39K
  • Biotronik Inc.$2K
  • Boston Scientific$1K
  • Cardiva Medical, Inc.$694
  • Biosense Webster, Inc.$354
  • Abbott$322
  • plus $642 from 9 others

What the payments were for

  • Grants$25,50058%
  • Travel & lodging$8,97920%
  • Food & beverage$9,21821%
  • Education$2251%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

Too few clinical cardiac electrophysiology providers in New Mexicoto place this figure against a meaningful peer group, so we don't.

Medicare billing

Part B allowed, 2024
$122,255
Medicare patients
911
Services billed
1,515

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban126$137,776
XareltoRivaroxaban76$87,988
Flecainide Acetate89$4,005
Amiodarone Hcl67$1,318
Metoprolol Succinate63$1,294
Diltiazem 24hr Er (Cd)Diltiazem Hcl13$451
Losartan Potassium25$295
Metoprolol Tartrate32$283
Spironolactone16$266
Furosemide36$260
Lisinopril21$255
Atorvastatin Calcium13$210
Rosuvastatin Calcium12$161
Carvedilol11$159
Mupirocin11$135

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$16$137,776126 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. There are too few clinical cardiac electrophysiology providers in New Mexicoon file to place this against a meaningful peer group, so we don't.

Other clinical cardiac electrophysiology in Albuquerque

See the full list for New Mexico

Where these figures come from

Is this you, or does something look wrong? →